- Email: [email protected]
New Neisseria mutants unable to induce production of blocking antibody; Neisseria gonorrhoeae and Neisseria meningitidis lacking gene for protein PIII, useful in production of protective antigen for vaccine
Patent Report This section provides information on worldwide patents relevant to vaccine design and production. The Patent Report gives the following information: title of patent, patentee, patent number, publication date and summary of the patent. A number of patents in this report are reproduced from ‘Biotechnology Abstracts’ with permission of Derwent Publications Ltd. New Neisseria mutants unable to induce production of blocking antibody ; Neisseria gonorrhoeae and Neisseria meningitidis lacking gene for protein PHI, useful in production of protective antigen for vaccine Rockefeller-Univ.
Eur 351 604; 24 January
virus strain NDW
CNCM
1990
Newcastle-disease virus NDW CNCM I-78 1 is new, and is a live vaccine against Newcastle disease. The vaccine preferably comprises over log,, 5.5 EID,, per dose. The vaccine may also contain infectious-bronchitis virus strains. Live vaccines based on strain NDW are completely safe and efficacious, even for young fowl with high maternal immunity, and so can be used at age one day or later. Loss of immunogenicity does not occur when the vaccine contains other live virus components, e.g. infectious-bronchitis virus. In an example, a group of one-dayold broiler fowl were tested for material immunity by the HImethod. 43 Fowl were vaccinated with log,, 5.4EOD,, by spray vaccination. At 3 and 6 weeks after vaccination, 21 and 22 birds, respectively, were challenged with log,, 6 EID,, of Herts 33 virus, administered ocularly. The control was two SPF fowl, 1 week older than the broilers. After the challenge at 3 week postvaccination, ail 21 birds survived, while after the challenge at 6 weeks postvaccination 20 of 22 survived. The SPF controls died. 071-90 Composition containing DNA sequence encoding protein vaccine; eliciting antibody recognizing Treponema hyodysenteriae antigen ML-Technol.
Ventures
Eur 350 715; 17 January
1990
An expression vector including a specified DNA sequence is new. The sequence encodes at least one protein which is capable of eliciting an antibody which recognizes one epitope of a Treponema hyodysenferiae antigen of mol.wt 19 00@90 000 (preferably 25 000-65 000). More specifically, the antibody recognizes the 38 kDa, 39 kDa or 60kDa antigen. The protein IS useful in a vaccine against pig dysentery, and may also be used In 026441 oxpo/oso5 1WI3 ‘0 1990 Butterworth-Hememann
510
Ltd
Vaccine, Vol. 8, October 1990
inactive
protein
Eur 352 250; 24 January
1990
The Bordetella pertussrs toxin gene with an amino acid codon insertion in the Sl subunit is claimed. The gene may be modified by site-directed mutagenesis photooxidation or chemical mutagenesis at Glu-129, His-35, Arg-9 or Ser-40, preferably at Glu-129. The gene may be cloned into claimed plasmlds pRIT20002, pRIT20008, pRIT13070, pRIT13268, pRIT13269, pRIT13270, or pRIT13271 and expressed in B. pertrrssis stram BPRA cells. The modified pertussis toxin is recognized by antipertussis toxin antibodies. A vaccinecontaining all or part of the recombinant modified pertussis toxin with additional mutation at Trp26 (which inactivates the toxin) for protection against pertussis; a method for protecting humans from pertussis by administering the vaccine; a method for transforming host cells: and a method for producing recombinant modified pertussls toxin are clalmed. The modified toxins may be produced by synthetic or by recombmant DNA techniques. 073-90
I-781; fowl live
Duphar
Eur 351 908; 24 January
Modified Bordetefla pertassis toxin gene; application in pertussis vaccine preparation SK-Biol.
1990
Biologically pure cultures of a mutant of Neisseria strain which cannot produce a protein (I) which elicits blocking antibodies or reacts immunologically with such antibodies are new. Also new are vaccines containing an antigen derived from such mutants incapable of producing functional PIII-like protein plus an acceptable excipient, and antigen free of PIII-like protein. (I) is a cell surface protein, especially a PIII-like protein such as PI11 or Class 4. Mutants are Neisseria gonorrhoeae or Neisseria meningitidis, specifically strains ATCC 53787, ATCC 53924 or ATCC53925. The antigen can be PI, PII, pilin, iipopolysaccharide or iron-binding proteins, and excipients are liposomes or proteosomes. The vaccines are used to protect humans and animals against Neisseria infections. They are uncontaminated by PHI-like protein (which elicits production of blocking antibody) since they are derived from strains genetically unable to express such proteins. 070-90 Newcastle-disease vaccine
the diagnosis of T. hyodysenteriae. In an example, Escherichia JM83 containing plasmid pTrep301 was grown in Luria broth containing 200pgml- ’ ampicillin for 18 h at 3237°C. Thw cells were harvested, lysed and disrupted by sonication. The pellet fraction after centrifugation contained a 40 kDa protein which was recognized in Western blot analysis by pig and mouse antisera raised against authentic 39 kDa T. hyodysenteriae protein. 072-90 coli strain
New antigenic protein derived from nonA,nonB hepatitis virus is useful in vaccine and diagnosis, and related antisera and DNA fragments; DNA sequence and DNA probe Genelabs,
U.S. Dept. Health-Human-Serv.
World 8912 462; 28 December
1989
A protem (I) is derived from an enterlcally transmitted nonA,nonB hepatitis virus (NANBHV), the genome of which contains a region homologous to the 133 kb DNA EcoRI insert present in plasmid pT2-KFl (ET1.l) carried in Escherichia coli BB4 (ATCC 67717). Also new are DNA fragments derived from NANBHV which contains a region which is homologous to one of four specified DNA sequences, recombinant protems (Ia) derived from such fragments, and vaccines contaimng (Ia). The proteins can be used to make monoclonal antibodies by usual processes. (I) and (Ia) are useful diagnostically for detectton of antibodies against NANBHV in serum, and also in vaccmes The DNA fragments can also be used to detect and assay NANBHV by hybridization. DNA probes are derived from a cloned sequence of the virus. These probes are useful for identifying and sequencing the entlre viral agent and for assaying the presence of the virus m an infected sample, using probe-specific amplification of virus-derived DNA 074-90 fragments. Haemophilus injuenzae pilus vaccine is used for protection against infection and to prevent transmission to and colonization of upper respiratory tract Bactes World 8912 460; 28 December 1989 A vaccine
for protection
against
infections
caused
by piliated
Haemophtlus influenzae organisms comprises a carrier and a whole H. influenzae pilus (vaccine pili), previously separated from other H. influenxr components. capable of ralslng the
Eur 351 604; 24 January
virus strain NDW
CNCM
1990
Newcastle-disease virus NDW CNCM I-78 1 is new, and is a live vaccine against Newcastle disease. The vaccine preferably comprises over log,, 5.5 EID,, per dose. The vaccine may also contain infectious-bronchitis virus strains. Live vaccines based on strain NDW are completely safe and efficacious, even for young fowl with high maternal immunity, and so can be used at age one day or later. Loss of immunogenicity does not occur when the vaccine contains other live virus components, e.g. infectious-bronchitis virus. In an example, a group of one-dayold broiler fowl were tested for material immunity by the HImethod. 43 Fowl were vaccinated with log,, 5.4EOD,, by spray vaccination. At 3 and 6 weeks after vaccination, 21 and 22 birds, respectively, were challenged with log,, 6 EID,, of Herts 33 virus, administered ocularly. The control was two SPF fowl, 1 week older than the broilers. After the challenge at 3 week postvaccination, ail 21 birds survived, while after the challenge at 6 weeks postvaccination 20 of 22 survived. The SPF controls died. 071-90 Composition containing DNA sequence encoding protein vaccine; eliciting antibody recognizing Treponema hyodysenteriae antigen ML-Technol.
Ventures
Eur 350 715; 17 January
1990
An expression vector including a specified DNA sequence is new. The sequence encodes at least one protein which is capable of eliciting an antibody which recognizes one epitope of a Treponema hyodysenferiae antigen of mol.wt 19 00@90 000 (preferably 25 000-65 000). More specifically, the antibody recognizes the 38 kDa, 39 kDa or 60kDa antigen. The protein IS useful in a vaccine against pig dysentery, and may also be used In 026441 oxpo/oso5 1WI3 ‘0 1990 Butterworth-Hememann
510
Ltd
Vaccine, Vol. 8, October 1990
inactive
protein
Eur 352 250; 24 January
1990
The Bordetella pertussrs toxin gene with an amino acid codon insertion in the Sl subunit is claimed. The gene may be modified by site-directed mutagenesis photooxidation or chemical mutagenesis at Glu-129, His-35, Arg-9 or Ser-40, preferably at Glu-129. The gene may be cloned into claimed plasmlds pRIT20002, pRIT20008, pRIT13070, pRIT13268, pRIT13269, pRIT13270, or pRIT13271 and expressed in B. pertrrssis stram BPRA cells. The modified pertussis toxin is recognized by antipertussis toxin antibodies. A vaccinecontaining all or part of the recombinant modified pertussis toxin with additional mutation at Trp26 (which inactivates the toxin) for protection against pertussis; a method for protecting humans from pertussis by administering the vaccine; a method for transforming host cells: and a method for producing recombinant modified pertussls toxin are clalmed. The modified toxins may be produced by synthetic or by recombmant DNA techniques. 073-90
I-781; fowl live
Duphar
Eur 351 908; 24 January
Modified Bordetefla pertassis toxin gene; application in pertussis vaccine preparation SK-Biol.
1990
Biologically pure cultures of a mutant of Neisseria strain which cannot produce a protein (I) which elicits blocking antibodies or reacts immunologically with such antibodies are new. Also new are vaccines containing an antigen derived from such mutants incapable of producing functional PIII-like protein plus an acceptable excipient, and antigen free of PIII-like protein. (I) is a cell surface protein, especially a PIII-like protein such as PI11 or Class 4. Mutants are Neisseria gonorrhoeae or Neisseria meningitidis, specifically strains ATCC 53787, ATCC 53924 or ATCC53925. The antigen can be PI, PII, pilin, iipopolysaccharide or iron-binding proteins, and excipients are liposomes or proteosomes. The vaccines are used to protect humans and animals against Neisseria infections. They are uncontaminated by PHI-like protein (which elicits production of blocking antibody) since they are derived from strains genetically unable to express such proteins. 070-90 Newcastle-disease vaccine
the diagnosis of T. hyodysenteriae. In an example, Escherichia JM83 containing plasmid pTrep301 was grown in Luria broth containing 200pgml- ’ ampicillin for 18 h at 3237°C. Thw cells were harvested, lysed and disrupted by sonication. The pellet fraction after centrifugation contained a 40 kDa protein which was recognized in Western blot analysis by pig and mouse antisera raised against authentic 39 kDa T. hyodysenteriae protein. 072-90 coli strain
New antigenic protein derived from nonA,nonB hepatitis virus is useful in vaccine and diagnosis, and related antisera and DNA fragments; DNA sequence and DNA probe Genelabs,
U.S. Dept. Health-Human-Serv.
World 8912 462; 28 December
1989
A protem (I) is derived from an enterlcally transmitted nonA,nonB hepatitis virus (NANBHV), the genome of which contains a region homologous to the 133 kb DNA EcoRI insert present in plasmid pT2-KFl (ET1.l) carried in Escherichia coli BB4 (ATCC 67717). Also new are DNA fragments derived from NANBHV which contains a region which is homologous to one of four specified DNA sequences, recombinant protems (Ia) derived from such fragments, and vaccines contaimng (Ia). The proteins can be used to make monoclonal antibodies by usual processes. (I) and (Ia) are useful diagnostically for detectton of antibodies against NANBHV in serum, and also in vaccmes The DNA fragments can also be used to detect and assay NANBHV by hybridization. DNA probes are derived from a cloned sequence of the virus. These probes are useful for identifying and sequencing the entlre viral agent and for assaying the presence of the virus m an infected sample, using probe-specific amplification of virus-derived DNA 074-90 fragments. Haemophilus injuenzae pilus vaccine is used for protection against infection and to prevent transmission to and colonization of upper respiratory tract Bactes World 8912 460; 28 December 1989 A vaccine
for protection
against
infections
caused
by piliated
Haemophtlus influenzae organisms comprises a carrier and a whole H. influenzae pilus (vaccine pili), previously separated from other H. influenxr components. capable of ralslng the